相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease
David Roofeh et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
S. Panopoulos et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis
Benjamin Korman
TRANSLATIONAL RESEARCH (2019)
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
Mike Becker et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide
Aleksey Mitev et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort
Stylianos Panopoulos et al.
AUTOIMMUNITY REVIEWS (2018)
Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature
Galia Zacay et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2018)
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
Gabriele Valentini et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis
Theodoros Dimitroulas et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Cytokines in the immunopathology of systemic sclerosis
Jasmin Raja et al.
SEMINARS IN IMMUNOPATHOLOGY (2015)
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Frank van den Hoogen et al.
ARTHRITIS AND RHEUMATISM (2013)
Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
Angelo De Lauretis et al.
JOURNAL OF RHEUMATOLOGY (2013)
Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma
Shun Kitaba et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
Korsa Khan et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis?
Theresa C. Barnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats
Giselle C. Melendez et al.
HYPERTENSION (2010)
Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database
Jerome Avouac et al.
JOURNAL OF RHEUMATOLOGY (2010)
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
D. Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
分享论文
